2012
DOI: 10.4187/respcare.01996
|View full text |Cite
|
Sign up to set email alerts
|

Endobronchial Malignant Fibrous Histiocytoma: Case Report of an Unusual Presentation and Palliative Flexible Bronchoscopic Resection

Abstract: Primary malignant fibrous histiocytoma (MFH) of the lung is a very rare neoplasm that usually presents as a parenchymal mass. Here we report an unusual case of primary MFH of the bronchus, showing relatively benign clinical features. We performed a palliative resection via flexible bronchoscopy, using a polypectomy snare. The patient has survived for over 2 years after being diagnosed with an endobronchial mass, later found to be MFH, and 14 months post-debulking. There is a possibility that endobronchial MFH … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 23 publications
0
5
0
Order By: Relevance
“…Ipsilateral pleural effusion can occur in 20% of the patients [5], and endobronchial lesions have also been reported [6]. Without intending to make a generalized statement about FDG uptake in primary pulmonary MFH because it is a type of tumor that is rarely seen in the lungs, in our case, the SUVmax was 9.7.…”
Section: Discussionmentioning
confidence: 75%
“…Ipsilateral pleural effusion can occur in 20% of the patients [5], and endobronchial lesions have also been reported [6]. Without intending to make a generalized statement about FDG uptake in primary pulmonary MFH because it is a type of tumor that is rarely seen in the lungs, in our case, the SUVmax was 9.7.…”
Section: Discussionmentioning
confidence: 75%
“…The multicenter, single-agent doxorubicin and phase III clinical trial of doxorubicin–ifosfamide chemotherapy in Europe indicates a higher tumor response and overall survival (OS) ( 16 ) (OR 9.90, 95% HR 0.44, 95%). Therefore, gemcitabine/docetaxel chemotherapy may be a good option for patients with doxorubicin or ifosfamide failure ( 17 ). According to the retrospective study of Jee Hung Kim ( 17 ), the MFH/UPS efficiency is 50%.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, gemcitabine/docetaxel chemotherapy may be a good option for patients with doxorubicin or ifosfamide failure ( 17 ). According to the retrospective study of Jee Hung Kim ( 17 ), the MFH/UPS efficiency is 50%. However, these chemotherapy regimens are highly toxic which may lead to treatment failure.…”
Section: Discussionmentioning
confidence: 99%
“…The majority of patients die within a period of 1 to 72 months. Endobronchial masses showed more favorable prognosis compare to other origins 8…”
Section: Introductionmentioning
confidence: 90%
“…Clinical presentations in pulmonary tumors, as with other types of lung cancers, depends more on the tumor location rather than the histological type. Primary pulmonary sarcomas often present as a large peripheral or hilar well-circumscribed mass, and may present as an endobronchial tumor in 10% of cases 8. The majority of patients present with symptoms of cough, chest pain, hemoptysis, or dyspnea.…”
Section: Introductionmentioning
confidence: 99%